U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.1700
    +0.2370 (+0.18%)
     
  • BTC-USD

    21,293.73
    +237.38 (+1.13%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna Inc (NASDAQ: MRNA) said it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.

  • The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) has prompted efforts to use the novel technology in other vaccines and therapeutics.

  • Pfizer is also developing an mRNA-based vaccine for shingles and expects to begin clinical trials in the second half of 2022.

  • If successful, both companies will compete with GlaxoSmithKline Plc's (NYSE: GSK) two-dose vaccine Shingrix, approved by the FDA in 2017.

  • Shingles typically develop in older adults infected with chickenpox, or the varicella-zoster virus, when younger. It is characterized by a painful rash that generally clears up within a month.

  • Moderna's shingles vaccine is being developed to target the varicella-zoster virus.

  • The Company is also developing a cancer vaccine and a shot against the herpes simplex virus-2, which causes genital herpes, a sexually transmitted disease.

  • Price Action: MRNA shares are down 2.97% at $142.02 during the market session on the last check Friday.

  • Photo by Spencer Davis from Pixabay

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.